CD47 is ubiquitously expressed on blood cells, which significantly compromises tumor specificity.463 The clinical study of magrolimab found that the number of red blood cells, hematocrit and hemoglobin decreased on the 2nd day of application of the drug and dropped to the lowest point on the 5th to 7th day. Here, CD47 is linked to neoplasm.